Cure Pharmaceutical Holding Corp. - FORM 10-K - EX-23.1 - CONSENT LETTER - March 30, 2020

Attached files

file filename
EX-32.2 - CERTIFICATION - Cure Pharmaceutical Holding Corp.curr_ex322.htm
EX-32.1 - CERTIFICATION - Cure Pharmaceutical Holding Corp.curr_ex321.htm
EX-31.2 - CERTIFICATION - Cure Pharmaceutical Holding Corp.curr_ex312.htm
EX-31.1 - CERTIFICATION - Cure Pharmaceutical Holding Corp.curr_ex311.htm
EX-21.1 - LIST OF SUBSIDIARIES - Cure Pharmaceutical Holding Corp.curr_ex211.htm
EX-10.18 - FORM OF RESTRICTED STOCK UNIT AGREEMENT - Cure Pharmaceutical Holding Corp.curr_ex1018.htm
EX-10.17 - FORM OF RESTRICTED STOCK AWARD AGREEMENT - Cure Pharmaceutical Holding Corp.curr_ex1017.htm
EX-10.16 - FORM OF STOCK OPTION AGREEMENT - Cure Pharmaceutical Holding Corp.curr_ex1016.htm
EX-10.15 - AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN - Cure Pharmaceutical Holding Corp.curr_ex1015.htm
EX-4.2 - DESCRIPTION OF REGISTRANT'S SECURITIES - Cure Pharmaceutical Holding Corp.curr_ex42.htm
EX-4.1 - SPECIMEN COMMON STOCK CERTIFICATE - Cure Pharmaceutical Holding Corp.curr_ex41.htm
10-K - FORM 10-K - Cure Pharmaceutical Holding Corp.curr_10k.htm

EXHIBIT 23.1 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-227791) of CURE Pharmaceutical Holding Corp and subsidiaries of our report, which includes an explanatory paragraph regarding the substantial doubt about the Company's ability to continue as a going concern, dated March 30, 2020, relating to the consolidated financial statements, appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2019.

 

/s/ RBSM LLP

 

RBSM LLP

Henderson, NV

March 30, 2020

 

Cure Pharmaceutical Holding Corp. Reports